This report was recently updated on November 19 2024 with the latest and most recent
market numbers
Global mRNA Vaccines Market Size, Trends & Analysis - Forecasts to 2028 By Application (HIV AIDS, Cancer, Respiratory Diseases, Others), By End-Use (Hospitals & Clinics, Ambulatory Surgical Centres, Research Institutes, Others), By Region (North America, Asia Pacific, Central & South America, Europe, and the Middle East & Africa), End-User Landscape Analysis, Company Market Share Analysis, and Competitor Analysis
The global mRNA vaccines market is projected to grow at a CAGR of 13.03% from 2023 to 2028.
The market for mRNA vaccines is gaining traction as it offers numerous advantages over other nucleic acid-based vaccines. The mRNA vaccine can be produced quickly and cheaply, which increases its market demand. As part of a treatment option, the mRNA vaccine is a nucleic acid-based vaccine containing messenger RNAs that allow the patient's cells to produce proteins. These vaccines have self-adjuvant properties. To generate a strong immune response, the mRNA vaccine uses the host cell machinery to translate the mRNA into its corresponding antigen. The use of mRNA vaccines eliminates the possibility of infectious particles being produced in the body. Traditional medicines are outperformed by mRNA-derived products in terms of efficacy, immunogenicity, and manufacturing cost.
Due to the consumption of advanced medical technologies, higher quality of services, efficiency, and novel pharmaceutical innovations, the market is estimated to drive during the forecast period. mRNA vaccine market though lacks flexibility and sustainability. This might hinder the market but the cost-effective manufacturing processes and a long-term need for mRNA vaccines will propel the growth in the long run.
Following the emergence of the COVID-19 pandemic, mRNA therapeutics and mRNA vaccines have received considerable attention as a revolutionary novel drug class for the treatment of COVID-19, as well as a variety of other diseases such as oncological disorders, infectious diseases, and genetic disorders. Many mRNA vaccines are currently in development or commercialization for a variety of indications. As a result, there is a clear increase in demand for mRNA vaccine capacity.
Due to the pandemic, the global mRNA vaccine saw a significant growth rate as pharmaceutical companies focused on mRNA-based vaccines. As new strains of COVID-19 are appearing in various countries, the demand for mRNA-based vaccines will only increase more during the forecast period.
The hospitals & clinics segment is expected to witness the largest share in the global mRNA vaccines market during the forecast period of 2023-2028. Due to an increase in desk jobs and long hours, lifestyles have changed drastically over the years. This increases non-communicable diseases such as cancer, diabetes, cardiovascular diseases, and many others.
According to the World Health Organization, breast cancer cases in the United States are expected to increase by approximately 50% by 2030. Lifestyle diseases, such as poor eating habits, smoking, and a lack of exercise, cause health problems such as breathing difficulties and low body oxygen levels regardless of age, gender, or heredity. The rising prevalence of lifestyle diseases is expected to be a major driver of the hospitals and clinics segment.
The research institutes segment is expected to grow the fastest during 2023-2028. Research institutes conduct clinical research that bridges the current gaps and identifies treatment plans for existing stem cell projects. This increased awareness in research, additional funding, and government initiatives save time and cost of production with efficiency and consistency.
The cancer segment is expected to witness the largest share in the global mRNA vaccine market during the forecast period of 2023-2028. For nearly a decade, mRNA-based cancer treatment vaccines have been tested in small trials, with some promising early results.
In fact, both Pfizer-BioNTech and Moderna scientists used their experience of developing mRNA cancer vaccines to develop coronavirus vaccines. Some researchers believe that the success of the mRNA COVID-19 vaccines will help accelerate clinical research on mRNA vaccines for cancer treatment. mRNA treatment vaccines are being tested in dozens of clinical trials in people with various cancers, including pancreatic cancer, colorectal cancer, and melanoma. Some vaccines are being tested in conjunction with drugs that boost the immune system's response to tumours. As a result, the vaccine development segment is expected to have the highest share.
The respiratory diseases segment is expected to grow the fastest during 2023-2028. Global implementation of messenger RNA (mRNA) vaccines represents an enormous advancement with far-reaching implications for respiratory disease treatment. mRNA vaccines have high efficacy and the ability to adapt to new viruses and variants.
mRNA vaccines are capable of long-lasting and tissue-specific memory responses. These are required for rapid recall and immediate local protection. Such advances in the development of next-generation mRNA vaccines boost the segment. Furthermore, advances in pulmonary delivery technologies also tend to overcome the challenges like lung-stable formulation design, navigating pulmonary biological barriers, lack of predictive models, and measurement of techniques.
The North America segment is expected to witness the largest share in the global mRNA vaccines market during the forecast period of 2023-2028. Due to an increase in research in the healthcare segment, the North America segment will dominate the global mRNA vaccines market. Significant research funding, expanded federal programs aimed at RNA-based medicines, and an increase in the number of clinical trials will drive the market in North America. For example, in November 2020, the National Institutes of Health (NIH), the Defence Department, and federally funded academic laboratories all supported Graham and others' basic research, which was critical in the rapid development of COVID-19 vaccines.
An increase in the standard of living, and new technologies in the medical sector are a few reasons which drive the market in the United States. As one of the most developed nations in the world, the United States is a hub for complex medical treatments for many people around the world. The mRNA vaccine industry in the United States has been substantially strong for a few years due to the increasing demand for consumers in the healthcare domain, and it is estimated to grow further during the forecast period.
Asia-Pacific is expected to grow the fastest during 2023-2028. The Asia-Pacific region has been developing a huge infrastructure for the healthcare sector and many medical advancements via research. Countries like India and China are advancing their technology rapidly. India, for example, has developed covid vaccines rapidly and this will further drive the market during the forecast period.
There is also substantial growth due to investments in research and development especially in stem cell research due to the increase in chronic diseases. This competitive landscape helps in the growth rate of the global mRNA vaccine market. Furthermore, renowned companies are expanding their business in Europe for treatments and research therapies.
Argos Therapeutics Inc., BioNTech AG, CureVac AG, ETheRNA Immunotherapies, Ethris GmbH, Incellart, Moderna Inc., Sangamo Therapeutics Inc., Tiba Biotech, and Translate Bio Inc., among others, are some of the key players in the mRNA vaccines market.
Please note: This is not an exhaustive list of companies profiled in the report.
Chapter 1 Research Methodology
1.1 Research Assumptions
1.2 Research Methodology
1.2.1 Estimates and Forecast Timeline
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 GME’s Internal Database
1.3.3 Primary Research
1.3.4 Secondary Sources & Third-Party Perspectives
1.3.4.1 Company Information Sources
1.3.4.2 Secondary Data Sources
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Data Visualization
1.6 Data Validation & Publishing
1.7 Market Model
1.6.1 Model Details
1.6.1.1 Top-Down Approach
1.6.1.2 Bottom-Up Approach
1.8 Market Segmentation & Scope
1.9 Market Definition
Chapter 2 Executive Summary
2.1 Global Market Outlook
2.2 End-Use Outlook
2.3 Application Outlook
2.4 Regional Outlook
Chapter 3 Global MRNA Vaccines Market Trend Analysis
3.1. Market Introduction
3.2 Penetration & Growth Prospect Mapping
3.3 Impact of COVID-19 on the MRNA Vaccines Market
3.4 Metric Data based on the industry
3.5 Market Dynamic Analysis
3.5.1 Market Driver Analysis
3.5.2 Market Restraint Analysis
3.5.3 Industry Challenges
3.5.4 Industry Opportunities
3.6 Porter’s Five Analysis
3.6.1 Supplier Power
3.6.2 Buyer Power
3.6.3 Substitution Threat
3.6.4 Threat from New Entrant
3.7 Market Entry Strategies
Chapter 4 MRNA Vaccines Market: By End-Use Trend Analysis
4.1 By End-Use: Historic Data vs. Forecast Data Analysis, 2022 vs. 2028
4.2 Hospitals & Clinics
4.2.1 Market Estimates & Forecast Analysis of Hospitals & Clinics Segment, By Region, 2019-2028 (USD Billion)
4.3 Ambulatory Surgical Centers
4.3.1 Market Estimates & Forecast Analysis of Ambulatory Surgical Centers Segment, By Region, 2019-2028 (USD Billion)
4.4 Research Institutes
4.4.1 Market Estimates & Forecast Analysis of Research Institutes Segment, By Region, 2019-2028 (USD Billion)
4.5 Others
4.5.1 Market Estimates & Forecast Analysis of Others Segment, By Region, 2019-2028 (USD Billion)
Chapter 5 MRNA Vaccines Market: By Application Trend Analysis
5.1 By Application: Historic Data vs. Forecast Data Analysis, 2022 vs. 2028
5.2 HIV-AIDS
5.2.1 Market Estimates & Forecast Analysis of HIV-AIDS, By Region, 2019-2028 (USD Billion)
5.3 Cancer
5.3.1 Market Estimates & Forecast Analysis of Cancer Market Segment, By Region, 2019-2028 (USD Billion)
5.4 Respiratory Diseases
5.4.1 Market Estimates & Forecast Analysis of Respiratory Diseases Segment, By Region, 2019-2028 (USD Billion)
Chapter 6 MRNA Vaccines Market, By Region
6.1 Regional Outlook
6.2 North America
6.2.1 Market Estimates & Forecast Analysis, By Country 2019-2028 (USD Billion)
6.2.2 Market Estimates & Forecast Analysis, By End-Use, 2019-2028 (USD Billion)
6.2.3 Market Estimates & Forecast Analysis, By Application, 2019-2028 (USD Billion)
6.2.4 U.S.
6.2.4.1 Market Estimates & Forecast Analysis, By End-Use, 2019-2028 (USD Billion)
6.2.4.2 Market Estimates & Forecast Analysis, By Application, 2019-2028 (USD Billion)
6.2.5 Canada
6.2.5.1 Market Estimates & Forecast Analysis, By End-Use, 2019-2028 (USD Billion)
6.2.5.2 Market Estimates & Forecast Analysis, By Application, 2019-2028 (USD Billion)
6.2.6 Mexico
6.2.6.1 Market Estimates & Forecast Analysis, By End-Use, 2019-2028 (USD Billion)
6.2.6.2 Market Estimates & Forecast Analysis, By Application, 2019-2028 (USD Billion)
6.3 Europe
6.3.1 Market Estimates & Forecast Analysis, By Country 2019-2028 (USD Billion)
6.3.2 Market Estimates & Forecast Analysis, By End-Use, 2019-2028 (USD Billion)
6.3.3 Market Estimates & Forecast Analysis, By Application, 2019-2028 (USD Billion)
6.3.4 Germany
6.3.4.1 Market Estimates & Forecast Analysis, By End-Use, 2019-2028 (USD Billion)
6.3.4.2 Market Estimates & Forecast Analysis, By Application, 2019-2028 (USD Billion)
6.3.5 UK
6.3.5.1 Market Estimates & Forecast Analysis, By End-Use, 2019-2028 (USD Billion)
6.3.5.2 Market Estimates & Forecast Analysis, By Application, 2019-2028 (USD Billion)
6.3.6 France
6.3.6.1 Market Estimates & Forecast Analysis, By End-Use, 2019-2028 (USD Billion)
6.3.6.2 Market Estimates & Forecast Analysis, By Application, 2019-2028 (USD Billion)
6.3.7 Russia
6.3.7.1 Market Estimates & Forecast Analysis, By End-Use, 2019-2028 (USD Billion)
6.3.7.2 Market Estimates & Forecast Analysis, By Application, 2019-2028 (USD Billion)
6.3.8 Italy
6.3.8.1 Market Estimates & Forecast Analysis, By End-Use, 2019-2028 (USD Billion)
6.3.8.2 Market Estimates & Forecast Analysis, By Application, 2019-2028 (USD Billion)
6.3.9 Spain
6.3.9.1 Market Estimates & Forecast Analysis, By End-Use, 2019-2028 (USD Billion)
6.3.9.2 Market Estimates & Forecast Analysis, By Application, 2019-2028 (USD Billion)
6.3.10 Netherlands
6.3.10.1 Market Estimates & Forecast Analysis, By End-Use, 2019-2028 (USD Billion)
6.3.10.2 Market Estimates & Forecast Analysis, By Application, 2019-2028 (USD Billion)
6.3.11 Rest of Europe
6.3.11.1 Market Estimates & Forecast Analysis, By End-Use, 2019-2028 (USD Billion)
6.3.11.2 Market Estimates & Forecast Analysis, By Application, 2019-2028 (USD Billion)
6.4 Asia Pacific
6.4.1 Market Estimates & Forecast Analysis, By Country 2019-2028 (USD Billion)
6.4.2 Market Estimates & Forecast Analysis, By End-Use, 2019-2028 (USD Billion)
6.4.3 Market Estimates & Forecast Analysis, By Application, 2019-2028 (USD Billion)
6.4.4 China
6.4.4.1 Market Estimates & Forecast Analysis, By End-Use, 2019-2028 (USD Billion)
6.4.4.2 Market Estimates & Forecast Analysis, By Application, 2019-2028 (USD Billion)
6.4.5 India
6.4.5.1 Market Estimates & Forecast Analysis, By End-Use, 2019-2028 (USD Billion)
6.4.5.2 Market Estimates & Forecast Analysis, By Application, 2019-2028 (USD Billion)
6.4.6 Japan
6.4.6.1 Market Estimates & Forecast Analysis, By End-Use, 2019-2028 (USD Billion)
6.4.6.2 Market Estimates & Forecast Analysis, By Application, 2019-2028 (USD Billion)
6.4.7 South Korea
6.4.7.1 Market Estimates & Forecast Analysis, By End-Use, 2019-2028 (USD Billion)
6.4.7.2 Market Estimates & Forecast Analysis, By Application, 2019-2028 (USD Billion)
6.4.8 Thailand
6.4.8.1 Market Estimates & Forecast Analysis, By End-Use, 2019-2028 (USD Billion)
6.4.8.2 Market Estimates & Forecast Analysis, By Application, 2019-2028 (USD Billion)
6.4.9 Indonesia
6.4.9.1 Market Estimates & Forecast Analysis, By End-Use, 2019-2028 (USD Billion)
6.4.9.2 Market Estimates & Forecast Analysis, By Application, 2019-2028 (USD Billion)
6.4.10 Malaysia
6.4.10.1 Market Estimates & Forecast Analysis, By End-Use, 2019-2028 (USD Billion)
6.4.10.2 Market Estimates & Forecast Analysis, By Application, 2019-2028 (USD Billion)
6.4.11 Singapore
6.4.11.1 Market Estimates & Forecast Analysis, By End-Use, 2019-2028 (USD Billion)
6.4.11.2 Market Estimates & Forecast Analysis, By Application, 2019-2028 (USD Billion)
6.4.12 Vietnam
6.4.12.1 Market Estimates & Forecast Analysis, By End-Use, 2019-2028 (USD Billion)
6.4.12.2 Market Estimates & Forecast Analysis, By Application, 2019-2028 (USD Billion)
6.4.13 Rest of Asia Pacific
6.4.13.1 Market Estimates & Forecast Analysis, By End-Use, 2019-2028 (USD Billion)
6.4.13.2 Market Estimates & Forecast Analysis, By Application, 2019-2028 (USD Billion)
6.5 Central & South America
6.5.1 Market Estimates & Forecast Analysis, By Country 2019-2028 (USD Billion)
6.5.2 Market Estimates & Forecast Analysis, By End-Use, 2019-2028 (USD Billion)
6.5.3 Market Estimates & Forecast Analysis, By Application, 2019-2028 (USD Billion)
6.5.4 Brazil
6.5.4.1 Market Estimates & Forecast Analysis, By End-Use, 2019-2028 (USD Billion)
6.5.4.2 Market Estimates & Forecast Analysis, By Application, 2019-2028 (USD Billion)
6.5.5 Argentina
6.5.5.1 Market Estimates & Forecast Analysis, By End-Use, 2019-2028 (USD Billion)
6.5.5.2 Market Estimates & Forecast Analysis, By Application, 2019-2028 (USD Billion)
6.5.6 Chile
6.5.6.1 Market Estimates & Forecast Analysis, By End-Use, 2019-2028 (USD Billion)
6.5.6.2 Market Estimates & Forecast Analysis, By Application, 2019-2028 (USD Billion)
6.5.7 Rest of Central & South America
6.5.7.1 Market Estimates & Forecast Analysis, By End-Use, 2019-2028 (USD Billion)
6.5.7.2 Market Estimates & Forecast Analysis, By Application, 2019-2028 (USD Billion)
6.6 Middle East & Africa
6.6.1 Market Estimates & Forecast Analysis, By Country 2019-2028 (USD Billion)
6.6.2 Market Estimates & Forecast Analysis, By End-Use, 2019-2028 (USD Billion)
6.6.3 Market Estimates & Forecast Analysis, By Application, 2019-2028 (USD Billion)
6.6.4 Saudi Arabia
6.6.4.1 Market Estimates & Forecast Analysis, By End-Use, 2019-2028 (USD Billion)
6.6.4.2 Market Estimates & Forecast Analysis, By Application, 2019-2028 (USD Billion)
6.6.5 United Arab Emirates
6.6.5.1 Market Estimates & Forecast Analysis, By End-Use, 2019-2028 (USD Billion)
6.6.5.2 Market Estimates & Forecast Analysis, By Application, 2019-2028 (USD Billion)
6.6.6 South Africa
6.6.6.1 Market Estimates & Forecast Analysis, By End-Use, 2019-2028 (USD Billion)
6.6.6.2 Market Estimates & Forecast Analysis, By Application, 2019-2028 (USD Billion)
6.6.7 Israel
6.6.7.1 Market Estimates & Forecast Analysis, By End-Use, 2019-2028 (USD Billion)
6.6.7.2 Market Estimates & Forecast Analysis, By Application, 2019-2028 (USD Billion)
6.5.8 Rest of Middle East & Africa
6.5.8.1 Market Estimates & Forecast Analysis, By End-Use, 2019-2028 (USD Billion)
6.5.8.2 Market Estimates & Forecast Analysis, By Application, 2019-2028 (USD Billion)
Chapter 7 Competitive Analysis
7.1 Key Global Players, Recent Developments & their Impact on the Industry
7.2 Four Quadrant Competitor Positioning Matrix
7.2.1 Key Innovators
7.2.2 Market Leaders
7.2.3 Emerging Players
7.2.4 Market Challengers
7.3 Vendor Landscape Analysis
7.4 End-User Landscape Analysis
7.5 Company Market Share Analysis, 2022
Chapter 8 Company Profile Analysis
8.1 Argos Therapeutics Inc.
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Strategic Initiatives
8.1.4 Product Benchmarking
8.2 BioNTech AG
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Strategic Initiatives
8.2.4 Product Benchmarking
8.3 CureVac
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Strategic Initiatives
8.3.4 Product Benchmarking
8.4 ETheRNA Immunotherapies
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Strategic Initiatives
8.4.4 Product Benchmarking
8.5 Ethris GmbH
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Strategic Initiatives
8.5.4 Product Benchmarking
8.6 Incellart
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Strategic Initiatives
8.6.4 Product Benchmarking
8.7 Moderma Inc.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Strategic Initiatives
8.6.4 Product Benchmarking
8.8 Sangamo Therapeutics Inc.
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Strategic Initiatives
8.7.4 Product Benchmarking
8.9 Tiba Biotech
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Strategic Initiatives
8.8.4 Product Benchmarking
8.10 Other Companies
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Strategic Initiatives
8.10.4 Product Benchmarking
List of Tables
1 Technological Advancements in the mRNA Vaccines Market
2 Global mRNA Vaccines Market: Key Market Drivers
3 Global mRNA Vaccines Market: Key Market Challenges
4 Global mRNA Vaccines Market: Key Market Opportunities
5 Global mRNA Vaccines Market: Key Market Restraints
6 Global mRNA Vaccines Market Estimates & Forecast Analysis, 2019-2028 (USD Billion)
7 Global mRNA Vaccines Market, By End-Use, 2019-2028 (USD Billion)
8 Hospitals & Clinics: Global mRNA Vaccines Market, By Region, 2019-2028 (USD Billion)
9 Ambulatory Surgical Centers: Global mRNA Vaccines Market, By Region, 2019-2028 (USD Billion)
10 Global MRNA Vaccines Market, By Application, 2019-2028 (USD Billion)
11 HIV-AIDS: Global MRNA Vaccines Market, By Region, 2019-2028 (USD Billion)
12 Respiratory Diseases: Global MRNA Vaccines Market, By Region, 2019-2028 (USD Billion)
13 Cancer: Global MRNA Vaccines Market, By Region, 2019-2028 (USD Billion)
14 Regional Analysis: Global MRNA Vaccines Market, By Region, 2019-2028 (USD Billion)
15 North America: MRNA Vaccines Market, By End-Use, 2019-2028 (USD Billion)
16 North America: MRNA Vaccines Market, By Application, 2019-2028 (USD Billion)
17 North America: MRNA Vaccines Market, By Country, 2019-2028 (USD Billion)
18 U.S: MRNA Vaccines Market, By End-Use, 2019-2028 (USD Billion)
19 U.S: MRNA Vaccines Market, By Application, 2019-2028 (USD Billion)
20 Canada: MRNA Vaccines Market, By End-Use, 2019-2028 (USD Billion)
21 Canada: MRNA Vaccines Market, By Application, 2019-2028 (USD Billion)
22 Mexico: MRNA Vaccines Market, By End-Use, 2019-2028 (USD Billion)
23 Mexico: MRNA Vaccines Market, By Application, 2019-2028 (USD Billion)
24 Europe: MRNA Vaccines Market, By End-Use, 2019-2028 (USD Billion)
25 Europe: MRNA Vaccines Market, By Application, 2019-2028 (USD Billion)
26 Europe: MRNA Vaccines Market, By Country, 2019-2028 (USD Billion)
27 Germany: MRNA Vaccines Market, By End-Use, 2019-2028 (USD Billion)
28 Germany: MRNA Vaccines Market, By Application, 2019-2028 (USD Billion)
29 UK: MRNA Vaccines Market, By End-Use, 2019-2028 (USD Billion)
30 UK: MRNA Vaccines Market, By Application, 2019-2028 (USD Billion)
31 France: MRNA Vaccines Market, By End-Use, 2019-2028 (USD Billion)
32 France: MRNA Vaccines Market, By Application, 2019-2028 (USD Billion)
33 Italy: MRNA Vaccines Market, By End-Use, 2019-2028 (USD Billion)
34 Italy: MRNA Vaccines Market, By Application, 2019-2028 (USD Billion)
35 Spain: MRNA Vaccines Market, By End-Use, 2019-2028 (USD Billion)
36 Spain: MRNA Vaccines Market, By Application, 2019-2028 (USD Billion)
37 Netherlands: MRNA Vaccines Market, By End-Use, 2019-2028 (USD Billion)
38 Netherlands: MRNA Vaccines Market, By Application, 2019-2028 (USD Billion)
39 Rest Of Europe: MRNA Vaccines Market, By End-Use, 2019-2028 (USD Billion)
40 Rest Of Europe: MRNA Vaccines Market, By Application, 2019-2028 (USD Billion)
41 Asia Pacific: MRNA Vaccines Market, By End-Use, 2019-2028 (USD Billion)
42 Asia Pacific: MRNA Vaccines Market, By Application, 2019-2028 (USD Billion)
43 Asia Pacific: MRNA Vaccines Market, By Country, 2019-2028 (USD Billion)
44 China: MRNA Vaccines Market, By End-Use, 2019-2028 (USD Billion)
45 China: MRNA Vaccines Market, By Application, 2019-2028 (USD Billion)
46 India: MRNA Vaccines Market, By End-Use, 2019-2028 (USD Billion)
47 India: MRNA Vaccines Market, By Application, 2019-2028 (USD Billion)
48 Japan: MRNA Vaccines Market, By End-Use, 2019-2028 (USD Billion)
49 Japan: MRNA Vaccines Market, By Application, 2019-2028 (USD Billion)
50 South Korea: MRNA Vaccines Market, By End-Use, 2019-2028 (USD Billion)
51 South Korea: MRNA Vaccines Market, By Application, 2019-2028 (USD Billion)
52 Thailand: MRNA Vaccines Market, By End-Use, 2019-2028 (USD Billion)
53 Thailand: MRNA Vaccines Market, By Application, 2019-2028 (USD Billion)
54 Indonesia: MRNA Vaccines Market, By End-Use, 2019-2028 (USD Billion)
55 Indonesia: MRNA Vaccines Market, By Application, 2019-2028 (USD Billion)
56 Malaysia: MRNA Vaccines Market, By End-Use, 2019-2028 (USD Billion)
57 Malaysia: MRNA Vaccines Market, By Application, 2019-2028 (USD Billion)
58 Singapore: MRNA Vaccines Market, By End-Use, 2019-2028 (USD Billion)
59 Singapore: MRNA Vaccines Market, By Application, 2019-2028 (USD Billion)
60 Vietnam: MRNA Vaccines Market, By End-Use, 2019-2028 (USD Billion)
61 Vietnam: MRNA Vaccines Market, By Application, 2019-2028 (USD Billion)
62 Middle East & Africa: MRNA Vaccines Market, By End-Use, 2019-2028 (USD Billion)
63 Middle East & Africa: MRNA Vaccines Market, By Application, 2019-2028 (USD Billion)
64 Middle East & Africa: MRNA Vaccines Market, By Country, 2019-2028 (USD Billion)
65 Saudi Arabia: MRNA Vaccines Market, By End-Use, 2019-2028 (USD Billion)
66 Saudi Arabia: MRNA Vaccines Market, By Application, 2019-2028 (USD Billion)
67 UAE: MRNA Vaccines Market, By End-Use, 2019-2028 (USD Billion)
68 UAE: MRNA Vaccines Market, By Application, 2019-2028 (USD Billion)
69 Israel: MRNA Vaccines Market, By End-Use, 2019-2028 (USD Billion)
70 Israel: MRNA Vaccines Market, By Application, 2019-2028 (USD Billion)
71 South Africa: MRNA Vaccines Market, By End-Use, 2019-2028 (USD Billion)
72 South Africa: MRNA Vaccines Market, By Application, 2019-2028 (USD Billion)
73 Central & South America: MRNA Vaccines Market, By End-Use, 2019-2028 (USD Billion)
74 Central & South America: MRNA Vaccines Market, By Application, 2019-2028 (USD Billion)
75 Central & South America: MRNA Vaccines Market, By Country, 2019-2028 (USD Billion)
76 Brazil: MRNA Vaccines Market, By End-Use, 2019-2028 (USD Billion)
77 Brazil: MRNA Vaccines Market, By Application, 2019-2028 (USD Billion)
78 Chile: MRNA Vaccines Market, By End-Use, 2019-2028 (USD Billion)
79 Chile: MRNA Vaccines Market, By Application, 2019-2028 (USD Billion)
80 Argos Therapeutics Inc.: Products Offered
81 BioNTech AG: Products Offered
82 CureVac: Products Offered
83 ETheRNA Immunotherapies: Products Offered
84 Ethris GmbH: Products Offered
85 Incellart: Products Offered
86 Tiba Biotech: Products Offered
87 Moderma Inc.: Products Offered
88 Sangamo Therapeutics Inc.: Products Offered
89 Other Companies: Products Offered
List of Figures
1. Global MRNA Vaccines Market Segmentation & Research Scope
2. Primary Research Partners and Local Informers
3. Primary Research Process
4. Primary Research Approaches
5. Primary Research Responses
6. Global MRNA Vaccines Market: Penetration & Growth Prospect Mapping
7. Global MRNA Vaccines Market: Value Chain Analysis
8. Global MRNA Vaccines Market Drivers
9. Global MRNA Vaccines Market Restraints
10. Global MRNA Vaccines Market Opportunities
11. Global MRNA Vaccines Market Challenges
12. Key MRNA Vaccines Market Manufacturer Analysis
13. Global MRNA Vaccines Market: Porter’s Five Forces Analysis
14. PESTLE Analysis & Impact Analysis
15. Argos Therapeutics Inc.: Company Snapshot
16. Argos Therapeutics Inc.: Swot Analysis
17. BioNTech AG: Company Snapshot
18. BioNTech AG: Swot Analysis
19. CureVac: Company Snapshot
20. CureVac: Swot Analysis
21. ETheRNA Immunotherapies: Company Snapshot
22. ETheRNA Immunotherapies: Swot Analysis
23. Ethris GmbH: Company Snapshot
24. Ethris GmbH: Swot Analysis
25. Tiba Biotech: Company Snapshot
26. Tiba Biotech: Swot Analysis
27. Moderma Inc.: Company Snapshot
28. Moderma Inc.: Swot Analysis
29. Sangamo Therapeutics Inc.: Company Snapshot
30. Sangamo Therapeutics Inc.: Swot Analysis
31. Incellart: Company Snapshot
32. Incellart: Swot Analysis
33. Other Companies: Company Snapshot
34. Other Companies: SWOT Analysis
The Global mRNA Vaccines Market has been studied from the year 2019 till 2028. However, the CAGR provided in the report is from the year 2023 to 2028. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.
The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the mRNA Vaccines Market.
The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.
Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.
Frequently Asked Questions
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
Or view our licence options:
Tailor made solutions just for you
80% of our clients seek made-to-order reports. How do you want us to tailor yours?
OUR CLIENTS
